Levodopa works. That is not in dispute — for most people with Parkinson's it works well, and often for years. The trouble is what it does not do. It replaces a chemical your brain has stopped producing in sufficient quantity; it does nothing about the reason your brain stopped producing it. The dopamine-producing neurons keep dying on the same schedule they were on before.
Closing that gap — not better symptom control, but slowing the loss itself — is what the stem cell research is actually chasing.
The case for MSCs in Parkinson's
Protection
MSCs release growth factors that appear to help dopamine-producing neurons survive stress that would otherwise kill them. In animal models this turns up consistently: treated animals lose fewer of those neurons, and they move better than untreated ones.
Inflammation
Parkinson's brains show chronic, low-grade inflammation, and there is decent reason to think it is not merely a bystander — that it actively accelerates the neuron loss. MSCs quiet that inflammatory state. If inflammation is genuinely part of the engine driving the disease forward, taking pressure off it ought to matter.
What the human data does and doesn't show
Early-phase studies in people have reported:
Improvements in motor scores at three to six months — rigidity and slowness of movement more than tremor
Reduced "off" time, when medication is working less well
Gains in the non-motor symptoms nobody discusses enough: sleep, mood, autonomic function
Two caveats you deserve up front. These are small studies, generally without the placebo controls that would make results airtight. And Parkinson's has a well-documented placebo response, which means early enthusiasm has to be treated with suspicion until larger trials land.
Response looks better in early and mid-stage disease. In advanced Parkinson's, a large share of the relevant neurons are already gone — there is simply less left to protect.
That last point is not a sales line, and it cuts both ways. It argues against waiting if you intend to do this at all. It argues equally for realism if you are already well along.
Route of delivery
The physicians weigh intrathecal delivery — into the spinal canal, closer to the central nervous system — against IV infusion, based on your stage and clinical picture. Intranasal delivery is being explored in research as a more direct path to the brain, but it is not a settled protocol and we are not going to present it as one.
The honest ceiling
MSC therapy does not cure Parkinson's, and it does not bring back neurons that are already gone. Anyone telling you otherwise is selling something.
What it may do is slow the rate of loss, quiet the inflammation, and — in some patients — produce functional improvement you can actually feel. On your consultation call you will get published response rates and a candid read on your own case, not a pitch.